Sun Phama Advanced Research Company (SPARC), has suffered another setback during the third quarter ended December 2018 and its net loss amounted to Rs.58.07 crore as against Rs.66.02 crore in the corresponding period of last year.
Its net sales declined to Rs.19.42 crore from Rs.23.05 crore. EPS worked out to negative Rs.2.34 as compared to negative Rs.2.67 in the last period.
For the nine months ended December 2017, its net sales declined sharply 58.3 per cent to Rs.58.17 crore from Rs.139.42 crore in the similar period of last year. Its net profit went up to Rs.199.48 crore from Rs.87.15 crore. The company has allotted 40.40 lakh equity shares of face value Re1 each pursuant to conversion of equivalent number of warrants held by the respective warrant holders upon exercise of conversion option by the respective concerned warrant holders. Due to this its equity capital increased to Rs.25.09 crore from Rs.24.69 crore.
SPARC scrip declined by Rs.21.20 today to Rs.477.35 from previous day's close of Rs.498.55 on BSE.
Its net sales declined to Rs.19.42 crore from Rs.23.05 crore. EPS worked out to negative Rs.2.34 as compared to negative Rs.2.67 in the last period.
For the nine months ended December 2017, its net sales declined sharply 58.3 per cent to Rs.58.17 crore from Rs.139.42 crore in the similar period of last year. Its net profit went up to Rs.199.48 crore from Rs.87.15 crore. The company has allotted 40.40 lakh equity shares of face value Re1 each pursuant to conversion of equivalent number of warrants held by the respective warrant holders upon exercise of conversion option by the respective concerned warrant holders. Due to this its equity capital increased to Rs.25.09 crore from Rs.24.69 crore.
SPARC scrip declined by Rs.21.20 today to Rs.477.35 from previous day's close of Rs.498.55 on BSE.